Sino Bio and Boehringer Ink 7B Cancer Deal
Sino Biopharmaceutical and Boehringer Ingelheim have agreed to a major oncology partnership covering six preclinical programs. The deal could generate up to seven billion dollars in milestone payments for the Chinese drugmaker.
Xurve View
Perspectivas:
Xurve View
Sino Biopharmaceutical signed a $7 billion cancer drug licensing deal with Boehringer Ingelheim during Wednesday morning trade. The agreement covers six preclinical oncology programs spanning antibody-drug conjugates and T-cell engagers. The partnership marks the second oncology collaboration between the two drugmakers.
